Iproniazid* (1-isonicotinyl-2-isopropyl-hydrazine) was initially introduced to clinical medicine as an antituberculous agent in 1952.1 Although potent in its therapeutic effect, the drug was eventually abandoned in favor of its chemical relative, isoniazid, largely because of its distressing side-effects. In addition to its antituberculous activity, early studies with iproniazid clearly indicated a striking nonspecific action in promoting elevation of mood, stimulating appetite, and increasing sense of well-being. In view of these nonspecific effects, the drug has been recently reintroduced as a "psychic energizer" in the management of psychiatric depression, with favorable results.2,3 Furthermore, there are indications that this agent is now being used in a large variety of medical disorders. Reports concerning the use of iproniazid in hypertension,4 rheumatoid arthritis,5 and angina pectoris6 have already appeared in the literature.
Of the early-recognized side-effects of iproniazid, those resulting from undesirable actions on the autonomic and central nervous systems are most frequent. These
FELIX A, SCHWARTZ E, RIFKIN H. Iproniazid HepatitisReport of Five Cases and Review of Pertinent Literature. AMA Arch Intern Med. 1959;104(1):72–82. doi:10.1001/archinte.1959.00270070074010